You may leave me a review on these links:

Ongoing clinical trials

We’re committed to advancing medicine by finding new and improved ways to diagnose and treat cancer that deliver better life outcomes for patients across the world

Ongoing clinical trials 12 clinical trials

Cancer

Multiple Myeloma study CC-220

Multiple Myeloma study CC-220

A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

Ongoing 2022

Cancer

LIT study

Breast cancer

Evaluation of LIT test as a marker for immunocompetence in chemotherapy

Ongoing 2022

Cancer

DCISionRT® Registry

Breast cancer

A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy

Ongoing 2022

Cancer

Greco2

Pancreatic cancer

GRECO-2: A Randomized, Phase 2 Study of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4711 in the Treatment of Unresectable or Borderline Resectable, Nonmetastatic Pancreatic Cancer

Ongoing 2022

Cancer

Bruin CLL 321

Lymphoma

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated CLL/Small Lymphocytic Lymphoma

Ongoing 2022

Cancer

Checkmate 7DX

Prostate

A Study of Nivolumab or Placebo in Combination with Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer - CheckMate 7DX

Ongoing 2022

Cancer

MCL study

Lymphoma

A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma

Ongoing 2022

Cancer

MK-1026

Multiple Myeloma

A Phase 2/3 Relapsed and/or Refractory Multiple Myeloma study

Ongoing 2022

Cancer

The Coastal Study

Non-Hodgkin’s Lymphoma

A Phase 3, Randomized, Open-Label, Controlled Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin’s Lymphoma

Ongoing 2022

Cancer

Assure

Chronic Lymphocytic Leukemia

A Phase 3b, Multicenter, Open-Label, Single-Arm Study of Acalabrutinib (ACP-196) in Subjects with Chronic Lymphocytic Leukemia

Ongoing 2022

Cancer

Multiple Myeloma Study C16029

Haematologic Malignancies

A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 in Participants with Hematologic Malignancies

Ongoing 2022

Cancer

The Tidal study

Lymphoma

A Multicenter, Open-Label, Single-Arm, Phase 2 Study of Zandelisib in Subjects with Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Systemic Therapies

Ongoing 2021

No Results